Prostate Cancer

CureVac is pioneering the use of mRNA technology in prostate cancer treatment with its RNActive platform. The CV9103 and CV9104 vaccines target prostate cancer, offering promising applications in castration-resistant and high-risk scenarios. Efforts to integrate combination therapies and personalized cancer vaccines signify a leap forward in delivering targeted, effective treatments to enhance patient outcomes. CureVac’s […]